TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05075772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765080
Description: BI 765080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765080
Description: BI 765080
Study: NCT05265520

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: His-CRT implantation
Description: The pathophysiological process is utilized in His-Bundle corrective pacing, resulting in a faster and more homogeneous activation of the heart pacing directly via the intrinsic conduction system of the heart accompanied by a right atrial endocardial lead and a right ventricular endocardial lead.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BIV-CRT implantation
Description: Biventricular cardiac resynchronization therapy has been shown to improve outcomes by delivering synchronized electrical stimuli to the right and left ventricles utilizing an an endocardial right atrial lead, an endocardial right ventricular lead, and an epicardial left ventricular lead implanted in a branch of the coronary sinus.
Study: NCT05636020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICARE Treatment
Description: The treatment is 12 teletherapy sessions lasting approximately 60-90 minutes. Of the 12 treatment sessions, 7 of them will focus on training skills to help the participant with TBI better recognize emotions from facial expressions. The remaining 5 sessions will teach skills important for empathizing with others' thoughts and feelings, and how to be emotionally supportive. Role-playing will be a big part of these last 5 sessions. The care-partner will be expected to attend as many of these 5 empathy sessions with the participant with TBI as possible.
Study: NCT05167760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraclonidine
Description: 1-2 drops per eye every 8 hours for 2 weeks
Study: NCT04913285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIN-2787
Description: KIN-2787 will be administered orally twice daily in 28-day cycles
Study: NCT04837170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional therapy + S (+)-Ketamine
Description: Patients who undergo general anesthesia using S(+)-ketamine hydrochloride for anesthesia induction,maintenance or postoperative analgesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional therapy
Description: Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
Study: NCT05891444

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency transcranial random noise
Description: High frequency tRNS is described as a non-invasive form of brain stimulation that uses a low-intensity, alternating current applied directly to the head through scalp electrodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham high frequency transcranial random noise
Description: In the sham condition, tRNS was delivered only during the ramp-up and ramp-down periods (30s); no current was delivered during the 30-minute intervention.
Study: NCT05517720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aria Trio complete Facial System
Description: Renew Serum, Brighten Serum, and Refine Serum.
Study: NCT06057740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT is a psychological intervention which targets cognitions and behaviors in attempt to change emotions.
Study: NCT06043570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Monitoring arm
Description: Patients will be follow-up using remote monitoring. In the RM follow-up arm, the patients are not mandated to visit the clinic unless there is unscheduled call due to adverse event notification.
Study: NCT05428982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative Modified Trendelenburg position
Description: Patients underwent the laparoscopic hysterectomy were positioned in a Modified Trendelenburg position (20 °) postoperative for 6 hours at ward.
Study: NCT04647487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3484356
Description: Administered orally.
Study: NCT06052215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Information Cards Education
Description: Providing family planning education to women through online information cards

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Information Cards Education
Description: Providing family planning education to women through online information cards
Study: NCT05911282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N Acetylcysteine
Description: The study began at 7 pm, when the volunteers in NAC group drank the contents of a numbered cup with NAC (1.2 g of NAC). At 9 pm, they were given the second cup with 1.2 g of NAC corresponding to their randomized number.~The cups with pure substance NAC were prepared and numbered by the physician not attending the drinking just before the study.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lemon juice
Description: The study began at 7 pm, when the volunteers in placebo group drank the contents of a numbered cup with lemon juice. At 9 pm, they were given the second cup with lemon juice corresponding to their randomized number.~The cups with lemon juice were prepared and numbered by the physician not attending the drinking just before the study.
Study: NCT05381337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sideburns mini incision
Description: The investigators present a new method to calculate the shortest incision for zygomatic fracture, and use this method to calculate the sideburns mini incision for the surgical treatment of zygomatic arch fracture.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: coronal scalp incision
Description: Coronal scalp incisions were used as control group.
Study: NCT05783882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolgolimab
Description: 250 mg Q3W
Study: NCT06206954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyHealthPath Tool
Description: Tailored, brief online tool to help patients learn about weight treatment options

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyHealthPath Guide
Description: Informational material to help patients learn about weight treatment options
Study: NCT00997542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04457895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: educational yoga program
Description: Daily 15-min yoga sessions at home with the Le guide du yoga and the audio-guide, during 12 weeks.~One 90-min yoga-therapeutic education session/week (during 6 weeks) given by a physical therapist trained to postural yog (the first on site and by videoconference for the others)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no intervention
Description: no yoga session at home and no yoga -therapeutic educatuion session
Study: NCT04356170

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cisplatine 75 mg/m² administered at D1 of each cure, every 3 weeks by intravenous infusion in 1 hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoro Uracil
Description: 750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoro Uracil
Description: 750 mg/m²/j administered continuously at D1 to D5 of each cure, every 3 weeks by intravenous infusion ( so 120 hours)
Study: NCT05918081

Intervention type: OTHER
Intervention: Multi-Stage 20 m Shuttle Run Test
Description: The aerobic capacities of the participants will be evaluated with the Multi-Stage 20 m Shuttle Run Test, their agility levels with the Pro Agility Test, their core muscle endurance with the McGill Trunk Extensor and Flexor Endurance test and their peripheral muscle strength with the MicroFET® 2 handheld dynamometer.
Study: NCT05054842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retagliptin phosphate tablets、metformin sustained-release tablets
Description: Retagliptin phosphate tablets 100mg+ metformin sustained-release tablets 1500mg or 2000mg based on prior medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Retagliptin phosphate placebo tablets、metformin sustained-release tablets
Description: Retagliptin phosphate 100mg placebo tablets + metformin sustained-release tablets 1500mg or 2000mg based on prior medication
Study: NCT04781231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MusicCare® device
Description: The device consists of a headset and a touch pad. The patient can choose the style of music he prefers among 5. The 'U-shaped sequence' offered by MusicCare® is based on the principle of hypnoanalgesia. Musical induction is personalized according to the patient's preference. It will gradually lead to a hypnotic state of consciousness modified by variations in musical components such as rhythm, frequencies, orchestral formation and volume. A listening session lasts about 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device with quiet recorded music
Description: An mp3 device with headphones will be given to the patient. Caregivers will launch a quiet 20-minute music playlist

Intervention type: OTHER
Group type: OTHER
Intervention: Usual management of anxiety
Description: No specific intervention
Study: NCT05851911

Intervention type: BIOLOGICAL
Intervention: sars-cov-2 vaccine or infection
Description: Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2

Intervention type: BIOLOGICAL
Intervention: sars-cov-2 vaccine or infection
Description: Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2

Intervention type: BIOLOGICAL
Intervention: sars-cov-2 vaccine or infection
Description: Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2

Intervention type: BIOLOGICAL
Intervention: sars-cov-2 vaccine or infection
Description: Whether to vaccinate COVID-19 vaccine, or infect with sars-cov-2
Study: NCT06253858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter Placement with Solopass System
Description: This device is used as a guidance for placing a brain catheter to target the brain ventricles and decrease multiple brain passes, incorrect deployment and malfunctioning of the drain.
Study: NCT05389462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-601
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-601
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-601
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADCT-601
Description: Intravenous (IV) infusion
Study: NCT05903443

Intervention type: DIAGNOSTIC_TEST
Intervention: ancillary tests
Description: electroencephalogram, short latency somatosensory evoked potential, transcranial Doppler

Intervention type: DIAGNOSTIC_TEST
Intervention: ancillary tests
Description: electroencephalogram, short latency somatosensory evoked potential, transcranial Doppler
Study: NCT05389462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intravenous (IV) infusion
Study: NCT05220930

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot bath for heel warming
Description: In this study, in line with the literature, the attempt to apply heat with a foot bath will be carried out by immersing both legs of the newborn in a basin filled with 15-20 cm of water at 38-40C, 5 minutes before the heel blood collection, starting just below the knee level. The intervention will be applied while the newborn is held in an upright position on his mother's lap.

Intervention type: OTHER
Group type: OTHER
Intervention: Ineffective heel warming with thermofor
Description: Ineffective heel warming will be applied to the newborns in the control group with a thermofor containing 28C warm water for 5 minutes before the heel blood collection procedure. During the procedure, the general condition of the newborn and the changes in his skin will be observed closely. Heel blood collection will be performed by following the standard procedure steps that are routinely applied in the service.
Study: NCT05461495

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Group
Description: This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in Chinese and Korean American dementia caregivers has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is participation in an on-line chat group to provide peer support. The fourth component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease.
Study: NCT04908033

Intervention type: DEVICE
Intervention: pacemaker implantation
Description: pacemaker implantation

Intervention type: DEVICE
Intervention: pacemaker implantation
Description: pacemaker implantation
Study: NCT04328194

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Serum Autotaxin
Description: Marker

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum Autotaxin
Description: Marker
Study: NCT06574425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: long-term, high blood flow hemoadsorption therapy
Description: Group 1 is the routine treatment group, Group 2 is the extended time group, and Group 3 is the extended time and increased blood flow group
Study: NCT06212687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital pre-therapy patient education program (StartHjelp)
Description: After randomization the intervention group receives access to a pre-therapy informational app, presenting information about the treatment process, options, patient rights, user organizations, and self-help while on waiting list before mental health outpatient treatment. The information is presented stepwise through video and text, while also providing links to additional information if needed. The videos are made available to the patients gradually, with more general information about the treatment process first, and more specific information as the first session approaches. The patient has the opportunity to rewatch the videos as they please.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator intervention
Description: After randomization, while on waiting list, the control group gets sent all the same information as the intervention group in written form, by mail.
Study: NCT05630300

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PMC Sure Status COVID-19 Antigen Test
Description: COVID-19 professional use kit in out-patient departments

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PMC Sure Status COVID-19 Antigen Test
Description: COVID-19 professional use kit in out-patient departments

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Acon Flowflex COVID-19 Antigen Home Test
Description: COVID-19 self-test kits
Study: NCT06283927

Intervention type: PROCEDURE
Intervention: Re-resection
Description: Resection of the recurrent tumor

Intervention type: DRUG
Intervention: Temozolomide
Description: Re-challenge Temozolomide chemotherapy

Intervention type: DRUG
Intervention: Lomustine
Description: Second line chemotherapy with Lomustine

Intervention type: RADIATION
Intervention: Re-irradiation
Description: Re-irradiation with single dose, fractionated, or hypofractionated radiation of the recurrent tumor

Intervention type: PROCEDURE
Intervention: Experimental therapy
Description: Experimental phase I therapy with oncolytic virotherapy or immunotherapy (this list is not exhaustive)

Intervention type: OTHER
Intervention: Best supportive care
Description: Best supportive care, focused on alleviating symptoms
Study: NCT06325930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-HU6
Description: \[14C\]-HU6 following a single dose of HU6 in healthy, adult male subjects
Study: NCT04328194

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest x-ray
Description: chest x- ray will be done for the study group
Study: NCT04328194

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breast ultrasound or mammography
Description: Breast ultrasound or mammography will be done for the study group to diagnosis of breast cancer

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Histopathological examination of breast mass specimens
Description: by True cut or fine needle aspiration cytology

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging ( MRI) and Bone scan
Description: will be done for the study group

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Peripheral haemogram
Description: blood sample will be taken from the patients

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Renal and liver functions
Description: to exclude any other morbidity

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Prothrombin time and concentration
Description: blood sample will be taken from the patients
Study: NCT04913285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KIN-2787 and binimetinib
Description: KIN-2787 and binimetinib will be administered orally twice daily in 28-day cycles
Study: NCT04328194

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cancer Antigen 15-3 (CA15-3).
Description: will be done for the 2 groups

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cancer Antigen 15-3 (CA15-3).
Description: will be done for the 2 groups

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Full medical history
Description: full medical history will be taken from all patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full medical history
Description: full medical history will be taken from all patients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Full clinical examination
Description: full clinical examination will be done for the patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full clinical examination
Description: full clinical examination will be done for the patients
Study: NCT05901961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Whitfield solution
Description: The patient will receive 60 mL of Whitfield solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
Study: NCT06438146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Dosing regimen: In this study protocol, liraglutide dosing will be implemented as follows: Liraglutide will be started at a dose of 0.6 mg per day. Participants will be taught to use the injection pen and will be observed giving the first injection. The dose will then be increased by 0.6 mg each week to a maximum dosage of 3.0 mg per day at the end of 4 weeks.~This corresponds to the following dosing schedule:~Week 1: 0.6 mg per day for one week Week 2: 1.2 mg per day for one week Week 3: 1.8 mg per day for one week Week 4: 2.4 mg per day for one week Week 5-12: 3.0 mg per day for 8 weeks Week 13-24: No drug administration
Study: NCT04720261

Intervention type: DRUG
Group type: OTHER
Intervention: Caplacizumab
Description: Analyse of ADAMTS13 activity in patients with aTTP treated with Caplacizumab in order to help adapting the treatment with caplacizumab in TTP patients
Study: NCT06245551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/albuterol metered-dose inhaler 160/180 μg
Description: Budesonide/albuterol combination aerosol for inhalation, single dose (given as 2 actuations of 80/90 μg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/albuterol metered-dose inhaler 160/180 μg
Description: Budesonide/albuterol combination aerosol for inhalation, single dose (given as 2 actuations of 80/90 μg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo metered-dose inhaler
Description: Placebo aerosol for inhalation, single dose (given as 2 actuations)
Study: NCT05901961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc oxide nanoparticles solution
Description: The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
Study: NCT06245551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo metered-dose inhaler
Description: Placebo aerosol for inhalation, single dose (given as 2 actuations)
Study: NCT04898621

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 75g fructose solution
Description: Subjects will drink a bottle of 350 ml solution containing 75g fructose per day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 150g fructose solution
Description: Subjects will drink a bottle of 700 ml solution containing 150g fructose per day for 4 weeks.